Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
Top Cited Papers
Open Access
- 25 May 2007
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (6) , 1754-1764
- https://doi.org/10.1002/art.22600
Abstract
Objective: To assess the association between the initiation of anti–tumor necrosis factor α (anti‐TNFα) therapy and the risk of serious bacterial infections in routine care.Methods: This was a cohort study of patients with rheumatoid arthritis (RA) in whom specific disease‐modifying antirheumatic drugs (DMARDs) were initiated. Patients were Medicare beneficiaries ages 65 years and older (mean age 76.5 years) who were concurrently enrolled in the Pharmaceutical Assistance Contract for the Elderly provided by the state of Pennsylvania. A total of 15,597 RA patients in whom a DMARD was initiated between January 1, 1995 and December 31, 2003 were identified using linked data on all prescription drug dispensings, physician services, and hospitalizations. Initiation of anti‐TNFα therapy, cytotoxic agents other than methotrexate (MTX), noncytotoxic agents, and glucocorticoids was compared with initiation of MTX. The main outcome measure was serious bacterial infections that required hospitalization.Results: The incidence of serious bacterial infections was, on average, 2.2 per 100 patient‐years in this population (95% confidence interval [95% CI] 2.0–2.4). Glucocorticoid use doubled the rate of serious bacterial infections as compared with MTX use, independent of previous DMARD use (rate ratio [RR] 2.1 [95% CI 1.5–3.1]), with a clear dose‐response relationship for dosages >5 mg/day (for ≤5 mg/day, RR 1.34; for 6–9 mg/day, RR 1.53; for 10–19 mg/day, RR 2.97; and for ≥20 mg/day, RR 5.48 [Pfor trend < 0.0001]). Adjusted models showed no increase in the rate of serious infections among initiators of anti‐TNFα therapy (RR 1.0 [95% CI 0.6–1.7]) or other DMARDs as compared with initiators of MTX.Conclusion: In a large cohort of patients with RA, we found no increase in serious bacterial infections among users of anti‐TNFα therapy compared with users of MTX. Glucocorticoid use was associated with a dose‐dependent increase in such infections.Keywords
This publication has 37 references indexed in Scilit:
- Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeuticsPharmacoepidemiology and Drug Safety, 2006
- Gaps in care for rheumatoid arthritis: A population studyArthritis Care & Research, 2005
- Consistency of performance ranking of comorbidity adjustment scores in canadian and U.S. utilization dataJournal of General Internal Medicine, 2004
- Suppression of T cell responses by chondromodulin I, a cartilage‐derived angiogenesis inhibitory factor: Therapeutic potential in rheumatoid arthritisArthritis & Rheumatism, 2004
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Small-sample bias and corrections for conditional maximum-likelihood odds-ratio estimatorsBiostatistics, 2000
- Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectivesJournal of Clinical Epidemiology, 1993
- Regression Analysis of Multivariate Incomplete Failure Time Data by Modeling Marginal DistributionsJournal of the American Statistical Association, 1989